<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02687841</url>
  </required_header>
  <id_info>
    <org_study_id>201502003MIPB</org_study_id>
    <nct_id>NCT02687841</nct_id>
  </id_info>
  <brief_title>A Uremic Toxin Absorbent (AST-120) to Treat Hospital Acquired Acute Kidney Injury</brief_title>
  <official_title>A Uremic Toxin Absorbent (AST-120) to Treat Hospital Acquired Acute Kidney Injury - A Open Label Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital, Yun-Lin Branch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Taiwan University Hospital Hsin-Chu Branch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taoyuan General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hospital acquired acute kidney injury is an important negative outcome predictor for&#xD;
      hospitalized patients. Uremic toxins accumulated after a given renal insult. Some of these&#xD;
      uremic toxins are protein bound and may accumulated after renal impairment, owing to both&#xD;
      impaired filtration, and inflammation. Recent animal studies have reported that accumulation&#xD;
      of uremic toxins, namely indoxyl sulfate and p-cresol, would down regulate endothelial&#xD;
      progenitor cells and in turn affect renal recovery. Elimination of these protein bound uremic&#xD;
      toxins with an activated charcoal would help restore endothelial function. We will conduct a&#xD;
      double blinded randomized placebo controlled trial, which aims to determine that if oral&#xD;
      activated charcoal will retard progression of AKI. Also, a panel of markers for endothelial&#xD;
      function will also be determined.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total recovery of kidney function, which is defined as less than 1.5 times pre-morbid creatinine levels on the 10th day of intervention.</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total recovery of serum creatinine on Day 5</measure>
    <time_frame>5 days</time_frame>
    <description>defined with less than 1.5 times elevation of pre-morbid plasma creatinine level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Needing renal replacement therapy on day 10.</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of serum creatinine elevation</measure>
    <time_frame>10 days</time_frame>
    <description>as calculated with ratios between highest serum creatinine and pre-morbid creatinine during study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The degree of Indoxyl sulfate change on Day 10 (%)</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The degree of Indoxyl sulfate change on Day 5 (%)</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The degree of p-cresol change on Day 10 (%)</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The degree of p-cresol change on Day 5 (%)</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>AST-120 and PTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days Pentapentoxifylline 400mg QD for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pentapentoxifylline 400mg QD for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AST-120and pentoxyphylline (PTX)</intervention_name>
    <description>AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days pentoxyphylline 400mg QD PO x 10 days.</description>
    <arm_group_label>AST-120 and PTX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pentoxyphylline (PTX)</intervention_name>
    <description>pentoxyphylline 400mg QD PO x 10 days.</description>
    <arm_group_label>PTX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        This is a prospective randomized placebo controlled trial. All patients admitted to&#xD;
        participating centers with newly diagnosed acute kidney injury (AKI) will be screened for&#xD;
        eligibility. The diagnosis of AKI will be determined and staged according to the KIGO-AKI&#xD;
        Guideline.11 The inclusion criteria include:&#xD;
&#xD;
          1. Age â‰¥ 20 years old on the day of admission&#xD;
&#xD;
          2. AKI develops during admission, as defined with KDIGO-AKI Guideline,11 namely,&#xD;
             elevation of serum creatinine above 0.3mg/dL within two days, above 1.5times baseline.&#xD;
&#xD;
        Patients with the following conditions will be excluded:&#xD;
&#xD;
          1. Baseline estimated glomerular filtration rates (eGFR) less than 30ml/min/1.73m2 or&#xD;
             greater than 90ml/min/1.73m2 according to MDRD equation.&#xD;
&#xD;
          2. Acute kidney injury diagnosed in the indexed admission (according to baseline&#xD;
             creatinine)&#xD;
&#xD;
          3. Ileus or under fasting status&#xD;
&#xD;
          4. Previous gastrointestinal operation.&#xD;
&#xD;
          5. Chronic constipation, as defined with bowel movement less than three times a day. If&#xD;
             usage of oral laxatives can achieve bowel movement of more than 3 times a day, this&#xD;
             patient will not be excluded.&#xD;
&#xD;
          6. Patients had ever undergone any modality of renal replacement therapy (RRT)&#xD;
&#xD;
          7. Patients with major hemorrhage, as defined with requirement of blood transfusion&#xD;
             during index admission.&#xD;
&#xD;
          8. Patients with a biopsy proved or clinically diagnosed liver cirrhosis, Child&#xD;
             classification B or C.&#xD;
&#xD;
          9. Patients with a congestive heart failure of NYHA Class III or IV, or requirement of&#xD;
             inotropic agents.&#xD;
&#xD;
         10. Patients with a chronic lung disease requiring non-invasive or invasive positive&#xD;
             pressure ventilation.&#xD;
&#xD;
         11. Solid organ or hematological transplantation donors.&#xD;
&#xD;
         12. Patients who had been diagnosed as AKI in the index hospitalization, as defined with&#xD;
             KDIGO 2012 criteria.&#xD;
&#xD;
         13. Patients with oliguric acute kidney injury, as defined with less than 500cc/day.&#xD;
&#xD;
         14. Evidence of obstructive acute kidney injury under kidney echosonography.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YU-SHENG WU</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tao-Min Huang</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital, Yun-Lin Branch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wei-Shun Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital Hsin-Chu Branch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JUI-HSIANG LIN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taoyuan General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ya-Fei Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chan-Yu Lin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heng-Chih Pan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chih-Chin Kao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Medical University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tao-Min Huang</last_name>
    <phone>0972655730</phone>
    <email>taominhuang@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>KWAN-DUN WU</last_name>
    <phone>0972651011</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital Yun-Lin Branch</name>
      <address>
        <city>Douliou</city>
        <zip>640</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao-Min Huang</last_name>
      <phone>0972655730</phone>
      <email>taominhuang@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>February 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2016</study_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Taiwan University Hospital</investigator_affiliation>
    <investigator_full_name>National Taiwan University Hospital</investigator_full_name>
    <investigator_title>KWAN-DUN WU MD. PhD.</investigator_title>
  </responsible_party>
  <keyword>acute kidney injury</keyword>
  <keyword>indoxylsulfate</keyword>
  <keyword>p-cresol</keyword>
  <keyword>AST-120</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

